MX360149B - Derivados de pantotenato para el tratamiento de trastornos neurologicos. - Google Patents

Derivados de pantotenato para el tratamiento de trastornos neurologicos.

Info

Publication number
MX360149B
MX360149B MX2014013048A MX2014013048A MX360149B MX 360149 B MX360149 B MX 360149B MX 2014013048 A MX2014013048 A MX 2014013048A MX 2014013048 A MX2014013048 A MX 2014013048A MX 360149 B MX360149 B MX 360149B
Authority
MX
Mexico
Prior art keywords
treatment
neurologic disorders
pantothenate
derivatives
pantothenate derivatives
Prior art date
Application number
MX2014013048A
Other languages
English (en)
Other versions
MX2014013048A (es
Inventor
Vaino Andrew
Biestek Marek
Shkreli Martin
Original Assignee
Retrophin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrophin Inc filed Critical Retrophin Inc
Publication of MX2014013048A publication Critical patent/MX2014013048A/es
Publication of MX360149B publication Critical patent/MX360149B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a derivados de pantotenato para el tratamiento de trastornos neurológicos (tales como neurodegeneración asociada con la pantotenato cinasa), composiciones farmacéuticas que contienen tales compuestos, y su uso en el tratamiento de trastornos neurológicos.
MX2014013048A 2012-04-27 2013-04-26 Derivados de pantotenato para el tratamiento de trastornos neurologicos. MX360149B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261639602P 2012-04-27 2012-04-27
PCT/US2013/038458 WO2013163576A1 (en) 2012-04-27 2013-04-26 Pantothenate derivatives for the treatment of neurologic disorders

Publications (2)

Publication Number Publication Date
MX2014013048A MX2014013048A (es) 2015-04-10
MX360149B true MX360149B (es) 2018-10-24

Family

ID=48428654

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013048A MX360149B (es) 2012-04-27 2013-04-26 Derivados de pantotenato para el tratamiento de trastornos neurologicos.

Country Status (25)

Country Link
US (3) US8673883B2 (es)
EP (3) EP3112372B1 (es)
JP (3) JP6254151B2 (es)
KR (1) KR20150035550A (es)
CN (2) CN106977544B (es)
AU (3) AU2013251345B2 (es)
BR (1) BR112014026817A2 (es)
CA (1) CA2879314A1 (es)
CY (2) CY1118198T1 (es)
DK (2) DK2841438T3 (es)
ES (2) ES2708813T3 (es)
HK (1) HK1207863A1 (es)
HR (2) HRP20161389T1 (es)
HU (2) HUE029474T2 (es)
IN (1) IN2014DN09584A (es)
LT (2) LT3112372T (es)
MX (1) MX360149B (es)
PL (2) PL2841438T3 (es)
PT (2) PT3112372T (es)
RS (2) RS55319B1 (es)
RU (2) RU2018112720A (es)
SI (2) SI2841438T1 (es)
SM (1) SMT201600395B (es)
TR (1) TR201819263T4 (es)
WO (1) WO2013163576A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3112372T (pt) * 2012-04-27 2019-01-17 Retrophin Inc Derivados do pantotenato para o tratamento de distúrbios neurológicos
US9896464B2 (en) 2013-10-25 2018-02-20 Retrophin, Inc. Pantothenate derivatives for the treatment of neurological disorders
EP2868662A1 (en) * 2013-11-04 2015-05-06 Acies Bio d.o.o. Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
AU2016366977A1 (en) 2015-12-08 2018-07-12 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders
MX2019009342A (es) * 2017-02-07 2019-10-02 Retrophin Inc Formulaciones de fosmetpantotenato solido.
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676976A (en) 1950-12-04 1954-04-27 Nat Res Dev Synthesis of pantothenic acid-4' phosphate
US2870188A (en) 1955-10-03 1959-01-20 Hoffmann La Roche Process for the manufacture of pantothenic acid 4'-phosphate and its salts
RU2002110463A (ru) * 1999-09-21 2004-02-27 Басф Акциенгезелльшафт (De) Способ и микроорганизмы для получения пантосоединений
AU2002326412A1 (en) 2001-07-20 2003-03-03 Oregon Health And Science University Novel human nucleic acids encoding a pantothenate kinase and methods of use
HUP0500383A2 (hu) * 2002-07-03 2005-08-29 Basf Ag Mikroorganizmusok és eljárások pantotenát fokozott termelésére
CA2618335C (en) 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Antiviral phosphoramidates of 4'-substituted pronucleotides
PT3112372T (pt) * 2012-04-27 2019-01-17 Retrophin Inc Derivados do pantotenato para o tratamento de distúrbios neurológicos

Also Published As

Publication number Publication date
AU2013251345A1 (en) 2014-11-27
SI2841438T1 (sl) 2016-12-30
CN106977544B (zh) 2019-06-07
AU2017239508B9 (en) 2019-06-13
ES2708813T3 (es) 2019-04-11
US20140135294A1 (en) 2014-05-15
EP3489248A1 (en) 2019-05-29
PT2841438T (pt) 2016-11-22
AU2013251345B2 (en) 2017-08-31
JP2019206553A (ja) 2019-12-05
SI3112372T1 (sl) 2019-04-30
AU2017239508A1 (en) 2017-10-26
CN104520307B (zh) 2016-12-21
PL2841438T3 (pl) 2017-08-31
DK2841438T3 (en) 2016-11-28
CN104520307A (zh) 2015-04-15
WO2013163576A1 (en) 2013-10-31
JP2017141257A (ja) 2017-08-17
JP2015515496A (ja) 2015-05-28
MX2014013048A (es) 2015-04-10
CN106977544A (zh) 2017-07-25
EP3112372A1 (en) 2017-01-04
AU2017239508B2 (en) 2019-05-23
AU2017239508C1 (en) 2019-11-07
BR112014026817A2 (pt) 2017-07-18
DK3112372T3 (en) 2019-02-18
EP2841438A1 (en) 2015-03-04
SMT201600395B (it) 2017-01-10
RS55319B1 (sr) 2017-03-31
HUE029474T2 (en) 2017-02-28
CY1121238T1 (el) 2020-05-29
RU2014147739A (ru) 2016-06-20
US9181286B2 (en) 2015-11-10
LT3112372T (lt) 2019-01-10
CA2879314A1 (en) 2013-10-31
US20130289001A1 (en) 2013-10-31
RS58336B1 (sr) 2019-03-29
KR20150035550A (ko) 2015-04-06
EP2841438B1 (en) 2016-08-10
JP6560284B2 (ja) 2019-08-14
TR201819263T4 (tr) 2019-01-21
PT3112372T (pt) 2019-01-17
HRP20190038T1 (hr) 2019-02-22
CY1118198T1 (el) 2017-06-28
EP3112372B1 (en) 2018-11-07
HRP20161389T1 (hr) 2016-12-02
US20160015727A1 (en) 2016-01-21
US8673883B2 (en) 2014-03-18
PL3112372T3 (pl) 2019-05-31
LT2841438T (lt) 2016-11-10
HUE042199T2 (hu) 2019-06-28
IN2014DN09584A (es) 2015-07-17
JP6254151B2 (ja) 2017-12-27
US9629862B2 (en) 2017-04-25
RU2018112720A (ru) 2019-02-28
AU2019219733A1 (en) 2019-09-05
ES2600179T3 (es) 2017-02-07
HK1207863A1 (en) 2016-02-12
RU2653497C2 (ru) 2018-05-10

Similar Documents

Publication Publication Date Title
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
TN2015000278A1 (en) Autotaxin inhibitors
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
PH12016500094A1 (en) Autotaxin inhibitors
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
IN2014KN02601A (es)
GB201106743D0 (en) Novel compounds
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MY180165A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
IN2014DN09584A (es)
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
IN2015DN00085A (es)
GB201209015D0 (en) Novel compounds
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
EP2931718A4 (en) NOVEL PYRIDINE -2-CARBOXAMIDE DERIVATIVES, COMPOSITIONS COMPRISING SUCH COMPOUNDS AND METHODS OF TREATMENT THEREFOR
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors

Legal Events

Date Code Title Description
FG Grant or registration